L'intérêt à découvert pour BioCryst Pharma donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de BioCryst Pharma. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

BioCryst Pharma (NASDAQ:BCRX) Stock, Rapport sur les intérêts à découvert

BIOCRYST PHARMACEUTICALS INC

BioCryst Pharma

BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharmaceuticals Inc

News

BCRX

BioCryst Announces FDA Acceptance Of Its New Drug Application For Oral, Once Daily ORLADEYO In Hereditary Angioedema Patents Aged 2 To 11 Years

RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Outperform and raises the price target from $11 to $13.

Price Target

Reiteration

Analyst Ratings

RBC Capital Reiterates Outperform on BioCryst Pharma, Raises Price Target to $13

JP Morgan analyst Jessica Fye maintains BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Overweight and raises the price target from $10 to $13.

JP Morgan Maintains Overweight on BioCryst Pharma, Raises Price Target to $13

HC Wainwright &amp; Co. analyst Andrew Fein reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Buy and maintains $30 price target.

HC Wainwright & Co. Reiterates Buy on BioCryst Pharma, Maintains $30 Price Target

Needham analyst Serge Belanger maintains BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Buy and raises the price target from $15 to $17.

Needham Maintains Buy on BioCryst Pharma, Raises Price Target to $17

BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) on Monday reported first-quarter sales of $145.50 million, up 52.7% year over year, beating the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">consensus of $126.87 million</a>.
The increase was primarily due to $134.2 million (+$45.3 million yoy) in Orladeyo&#8217;s net revenue in the first quarter of 2025, compared to $88.9 million in the first quarter of 2024 (+51.0 percent yoy).&nbsp;
Orladeyo&#8217;s net revenue increased to $134.24 million&nbsp;from <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45190350/biocryst-reports-first-quarter-2025-financial-results-and-provides-business-update" rel="noreferrer noopener">$88.87 million a year ago</a>.
Net income for the first quarter of 2025 was $32 thousand, or $0.00 per share, compared to a net loss of $35.4 million, or $0.17 per share, for the <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">first quarter of 2024</a>.&nbsp;
Operating income for the first quarter of 2025 was $21.2 million, compared to an operating loss of $14.5 million for the first quarter of 2024. Non-GAAP operating income, excluding stock-based compensation expense, was $42.6 million for the first quarter of 2025, compared to a non-GAAP operating loss of $0.8 million for the first quarter of 2024.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/05/45193720/immunitybio-slapped-with-fda-refusal-to-file-letter-for-expanded-use-of-its-bladder-cancer-drug" rel="noreferrer noopener">ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug</a>
Guidance: BioCryst increased its 2025 outlook for Orladeyo revenue to $580 million and $600 million <a target="_blank" href="https://www.benzinga.com/25/02/43918295/biocryst-pharmaceuticals-reveals-interim-data-from-orladeyo-pediatric-trial-reports-mixed-q4-earnings" rel="noreferrer noopener">from $535 million and $550 million</a>.
The company now expects full year 2025 operating expenses will be $440 million to $450 million (previously $425 million to $435 million).
The company is accelerating its expectation for sustainable profitability and positive cash flows by a year.
The company now expects to deliver net income and positive cash flows for the full year 2025 (previously, both were expected for the full year 2026).
Positive cash flow refers to the improvement in cash, cash equivalents, restricted cash, and investments from year-end 2024 to year-end 2025, not including the impact of the $75 million Pharmakon prepayment made in April 2025.
Price Action:&nbsp;BCRX stock closed higher by 23.50% to $11.03&nbsp;on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45196561/loews-posts-mixed-q1-results-pipeline-strength-offsets-insurance-and-hotel-weakness" target="_blank" rel="noreferrer noopener">Loews Posts Mixed Q1 Results: Pipeline Strength Offsets Insurance And Hotel Weakness</a></li>
</ul>

Biotech

Earnings

Guidance

Health Care

Movers

Trading Ideas

General

BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors

U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining around 0.2% on Monday.
The Dow traded up 0.21% to 41,406.25 while the NASDAQ fell 0.41% to 17,903.64. The S&amp;P 500 also fell, dropping, 0.26% to 5,671.90.
Check This Out: <a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a>
Leading and Lagging Sectors Industrials shares rose by 0.2% on Monday.
In trading on Monday, energy stocks dipped by 1.9%.
Top Headline
The ISM services PMI rose to 51.6 in April versus a nine-month low level of 50.8 in the previous month March and topping market estimates of 50.6.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Hyperscale Data, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPUS#NASDAQ">GPUS</a>) shares shot up 202% to $4.14 after the company issued first-quarter and FY25 sales guidance.</li>
<li>Shares of Skechers U.S.A., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) got a boost, surging 25% to $61.70 after the company agreed to be acquired by 3G Capital for $63 per share.</li>
<li>BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) shares were also up, gaining 12% to $10.01 after the company reported a first-quarter sales beat.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Integra LifeSciences Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IART#NASDAQ">IART</a>) shares dropped 29% to $11.94 after the company reported a first-quarter adjusted EPS miss and cut its FY25 adjusted EPS guidance.</li>
<li>Shares of PTC Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTCT#NASDAQ">PTCT</a>) were down 18% to $40.87. The company announced results from the Phase 2 PIVOT-HD study of PTC518 in Stage 2 and Stage 3 Huntington&#8217;s disease patients.</li>
<li>TG Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>) was down, falling 16% to $36.53 after the company reported worse-than-expected first-quarter EPS results.</li>
</ul>
Commodities In commodity news, oil traded down 2.2% to $57.00 while gold traded up 2.5% at $3,323.40.
Silver traded up 0.6% to $32.455 on Monday, while copper rose 0.3% to $4.6875.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.06%, while Spain's IBEX 35 Index gained 0.40%. Germany's DAX 40 rose 0.87% and France's CAC 40 fell 0.58% during the session.
Asia Pacific Markets
Asian markets closed higher on Monday, with India's BSE Sensex rising 0.37%.
Economics
<ul>
<li>The S&amp;P Global services PMI was revised lower to 50.8 in April 2025 compared to a preliminary reading of 51.4.</li>
<li>The ISM services PMI rose to 51.6 in April versus a nine-month low level of 50.8 in the previous month March and topping market estimates of 50.6.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45192437/how-to-earn-500-a-month-from-williams-companies-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Williams Companies Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Equities

Eurozone

Intraday Update

Markets

GPUS

IART

PTCT

TGTX

Crude Oil Falls Over 2%; ISM Services PMI Rises In April

U.S. stocks were lower, with the Nasdaq Composite falling around 100 points on Monday.
Shares of Napco Security Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSSC#NASDAQ">NSSC</a>) rose sharply during Monday's session after the company reported better-than-expected <a href="https://www.benzinga.com/quote/NSSC/earnings">first-quarter financial results</a>.
NAPCO Security Techs reported quarterly earnings of 28 cents per share which beat the analyst consensus estimate of 27 cents per share. The company reported quarterly sales of $43.96 million which beat the analyst consensus estimate of $43.14 million.
Napco Security Technologies shares jumped 9.6% to $26.06 on Monday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Skechers U.S.A., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SKX#NYSE">SKX</a>) shares jumped 25% to $61.66 after the company agreed to be acquired by 3G Capital for $63 per share.</li>
<li>BioCryst Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) gained 12.2% to $10.02 after the company reported a first-quarter sales beat.</li>
<li>Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) gained 10% to $11.44.</li>
<li>Frontier Group Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULCC#NASDAQ">ULCC</a>) gained 9.2% to $3.67.</li>
<li>Nutex Health Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUTX#NASDAQ">NUTX</a>) climbed 8.7% to $124.64.</li>
<li>Gold Fields Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFI#NYSE">GFI</a>) rose 7.7% to $22.84.</li>
<li>Harmony Gold Mining Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>) shares gained 7% to $16.09.</li>
<li>Tsakos Energy Navigation Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) gained 6.2% to $18.13.</li>
<li>American Axle &amp; Manufacturing Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXL#NYSE">AXL</a>) climbed 5.4% to $4.2050. The company posted upbeat quarterly earnings on Friday.</li>
<li>Worthington Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) gained 5.2% to $54.69. Canaccord Genuity analyst Brian McNamara upgraded Worthington Enterprises from Hold to Buy and raised the price target from $54 to $67.</li>
<li>Tsakos Energy Navigation Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEN#NYSE">TEN</a>) shares rose 4.9% to $17.90.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

NSSC

NUTX

PONY

ULCC

Napco Security Technologies Posts Better-Than-Expected Results, Joins Skechers, BioCryst Pharmaceuticals And Other Big Stocks Moving Higher On Monday

WIIM

BioCryst Pharmaceuticals shares are trading higher after the company reported a Q1 sales beat.

<h3>Gainers</h3>
<ul>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock moved upwards by 106.2% to $0.95 during Monday's pre-market session. The company's market cap stands at $5.7 million. </li>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVF#NASDAQ">IVF</a>) stock rose 22.22% to $2.2. The company's market cap stands at $10.8 million. </li>
<li>Firefly Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIFF#NASDAQ">AIFF</a>) shares rose 15.63% to $3.78. The company's market cap stands at $30.5 million. </li>
<li>BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) shares rose 14.89% to $10.26. The market value of their outstanding shares is at $2.1 billion. As per the news, the Q1 earnings report came out today. </li>
<li>iBio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBIO#NASDAQ">IBIO</a>) stock moved upwards by 14.88% to $1.16. The company's market cap stands at $11.4 million. The company's, Q3 earnings came out yesterday. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares rose 11.31% to $6.79. The market value of their outstanding shares is at $139.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) stock declined by 89.9% to $1.7 during Monday's pre-market session. The company's market cap stands at $104.5 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock decreased by 21.53% to $0.59. The market value of their outstanding shares is at $6.7 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares fell 21.32% to $0.4. The market value of their outstanding shares is at $9.4 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares fell 16.21% to $1.5. The market value of their outstanding shares is at $19.9 million. </li>
<li>ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) stock decreased by 14.39% to $1.25. The market value of their outstanding shares is at $17.9 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares declined by 14.09% to $0.43. The company's market cap stands at $2.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIFF

APVO

IBIO

MODV

NCNA

PLRX

QNRX

RNAZ

12 Health Care Stocks Moving In Monday's Pre-Market Session

BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) reported quarterly sales of $145.53 million which beat the analyst consensus estimate of $126.87 million by 14.71 percent. This is a 56.89 percent increase over sales of $92.76 million the same period last year.

Earnings Beats

BioCryst Pharma Q1 Sales $145.53M Beat $126.87M Estimate

ACEL

ADEA

ADUS

AESI

AMRC

AOMR

AORT

ARES

AROC

AXSM

BCSF

BFAM

BNTX

BRBR

BRCC

BWXT

CERT

CORT

CRBG

CRGY

CSTL

CTRA

DENN

DMRC

DORM

EKSO

ESCA

EVER

FANG

FRPT

GBDC

GECC

Hims & Hers Health, Inc. Class A Common Stock

HIMS

HSIC

HSII

HSTM

ICHR

INSP

IPAR

IRMD

JBTM

JELD

JRVR

LSCC

MATX

MYPS

NBIX

NGVT

NMFC

NVTS

OCUL

OPAD

OTTR

PLMR

PLOW

PLTR

PLYA

PRAA

PRIM

RAIL

RAND

Earnings Scheduled For May 5, 2025

BioCryst Grants 48,000 RSUs To New Hires As Employment Inducement Under Nasdaq Rule

Cantor Fitzgerald analyst Steven Seedhouse initiates coverage on BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Overweight rating and announces Price Target of $20.

Initiation

Cantor Fitzgerald Initiates Coverage On BioCryst Pharma with Overweight Rating, Announces Price Target of $20

RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Outperform and maintains $11 price target.

RBC Capital Reiterates Outperform on BioCryst Pharma, Maintains $11 Price Target

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Buy and maintains $15 price target.

Needham Reiterates Buy on BioCryst Pharma, Maintains $15 Price Target

Management

BioCryst Pharmaceuticals' CFO Anthony Doyle Notified The Company Of His Intention To Resign From His Employment With The Company, Effective April 9, 2025

Citizens Capital Markets analyst Jonathan Wolleben reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Market Outperform and maintains $18 price target.

Citizens Capital Markets Reiterates Market Outperform on BioCryst Pharma, Maintains $18 Price Target

RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) with a Outperform and raises the price target from $10 to $11.

RBC Capital Reiterates Outperform on BioCryst Pharma, Raises Price Target to $11

Press Releases

BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BioCryst to Present at Upcoming Investor Conference

BioCryst to Report First Quarter 2025 Financial Results on May 5

BioCryst to Present at Upcoming Investor Conferences

BioCryst Appoints Steve Frank to Board of Directors

BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update

BioCryst Announces FDA Acceptance of NDA for ORLADEYO® (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years

Comments

BioCryst Pharma

Intérêt court

BioCryst Pharma (NASDAQ:BCRX) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL